Further investigations into breast cancer have previously yielded fundamental marker discoveries including Mki67+ as a prognostic marker, Cd44+/Cd24+ as a breast cancer stem cell marker, and Trop2 as another therapeutic target (Ricardo et al., 2011; Xiong et al., 2019; Liu et al., 2021). This evidence concerns the gene CD44 and breast carcinoma.